- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
TFRC AntibodyMouse Monoclonal Antibody (Mab)
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AM2075b | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
| AM2075b-ev20 | 20 ug 100 ul | In Stock | $ 95.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
TFRC Antibody - Product info | |
| Application | WB
|
| Primary Accession | P02786 |
| Other Accession | NP_001121620.1 |
| Reactivity | Human |
| Concentration | 0.25 mg/ml |
| Isotype | IgM |
| Clone Names | 514CT23.4.1 |
| Calculated MW | 84871 Da |
TFRC Antibody - Additional info | |
| Gene ID 7037 | |
| Other Names TFRC; Transferrin receptor protein 1; T9; p90; CD_antigen=CD71; Transferrin receptor protein 1, serum form | |
| Target/Specificity Purified His-tagged TFRC protein(Fragment) was used to produced this monoclonal antibody. | |
| Dilution WB~~1:100~250 | |
| Format Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Euglobin precipitation followed by dialysis against PBS. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions TFRC Antibody is for research use only and not for use in diagnostic or therapeutic procedures. | |
TFRC Antibody - Protein Information | |
| Name TFRC | |
| Function Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin receptor into specialized endosomes. Endosomal acidification leads to iron release. The apotransferrin-receptor complex is then recycled to the cell surface with a return to neutral pH and the concomitant loss of affinity of apotransferrin for its receptor. Transferrin receptor is necessary for development of erythrocytes and the nervous system (By similarity). A second ligand, the heditary hemochromatosis protein HFE, competes for binding with transferrin for an overlapping C-terminal binding site | |
| Cellular Location Cell membrane; Single-pass type II membrane protein. Melanosome. Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV | |
TFRC Antibody - Related products
AM2075a: TFRC Antibody (Ascites)
AP2949b: CD71 Antibody (C-term)
TFRC Antibody - Application data
-
TFRC Antibody (Cat. #AM2075b) western blot analysis in WiDr cell line lysates (35ug/lane).This demonstrates the TFRC antibody detected the TFRC protein (arrow).
TFRC Antibody - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin receptor into specialized endosomes. Endosomal acidification leads to iron release. The apotransferrin-receptor complex is then recycled to the cell surface with a return to neutral pH and the concomitant loss of affinity of apotransferrin for its receptor. Transferrin receptor is necessary for development of erythrocytes and the nervous system (By similarity). A second ligand, the heditary hemochromatosis protein HFE, competes for binding with transferrin for an overlapping C-terminal binding site.
REFERENCES
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Ucisik-Akkaya, E., et al. Mol. Hum. Reprod. 16(10):770-777(2010) Blonde-Cynober, F., et al. Ann. Biol. Clin. (Paris) 68(5):569-575(2010) Marsee, D.K., et al. Am. J. Clin. Pathol. 134(3):429-435(2010) Fernandez-Real, J.M., et al. Eur. J. Clin. Invest. 40(7):600-607(2010)